German compressor manufacturer Secop is positioning its hermetic hydrocarbon compressors to assist the coming mass roll-out of COVID-19 vaccines, stressing their ability to maintain stable temperatures throughout the cold chain, even at the ultra-low temperatures required by some of the new vaccines.
The company’s compressors and electronic control solutions have been officially certified by the World Health Organization (WHO) for this purpose.
“Our stationary and mobile solutions make us a reliable partner for leading companies supporting the development of a global ULT (ultra-low temperature) supply chain,” said Secop on its website. Temperatures required for vaccines vary widely, including some from 2°C to 8°C (35.6°F to 46.4°F), and others from -20°C down to -70°C (-4°F to -94°F).
Secop’s products can also be equipped with a Solar Direct Drive (SDD) solution, making them suitable for vaccine storage and transport in areas with limited or non-existing electricity grid.
The company is eyeing not only the upcoming COVID-19 vaccine roll-out, but also other mRNA vaccines, such as one for Ebola, and a number of cell and gene therapies. All of these require ultra-low storage and transportation temperatures throughout the cold chain.
The Secop portfolio suitable for medical uses includes the R290 SLVE18CN variable speed compressor launched in November last year. The company is also “working on a new dedicated range of compressors approved beyond the standard envelope and conditions already guaranteed today,” according to the company’s website. “More information for the new range will be released shortly.”
Our stationary and mobile solutions make us a reliable partner for leading companies supporting the development of a global ULT (ultra-low temperature) supply chainSecop